Award
National Institute on Aging 5R01AG075122-05
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
Recipient
University of Arizona
Award Amount
$1,353,297.00
Ceiling
$1,353,297.00
Awarded
May 25, 2026
Identifier
5R01AG075122-05
A multi-year NIH-funded Phase 2 clinical trial led by the University of Arizona to evaluate PhytoSERM for preventing menopause-associated decline in brain metabolism and cognition, focusing on women's health and Alzheimer's disease risk reduction.
Description
This project addresses multiple strategic directions of the National Institutes on Aging’s 2020-2025 plan, including developing interventions to maintain health and prevent age-related diseases, translating basic discovery into treatments, and supporting women’s health research. It is a Phase 2 clinical trial to determine safety and efficacy of PhytoSERM to sustain brain glucose metabolism and assess efficacy on cognitive function, vasomotor symptoms, sleep quality, and mood symptoms.